Royal UNIBREW A/S
Share buy-back program
Share buy-back program
COMPANY ANNOUNCEMENT NO 17/2025 - March 31, 2025
On February 25, 2025, Royal Unibrew initiated a share buy-back program, cf. company announcement no. 3/2025 of February 25, 2025.
The program is carried out under Art. 5 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 16, 2014, on market abuse, as amended (the Market Abuse Regulation - MAR) and the Commission Delegated Regulation (EU) No 2016/1052 of March 8, 2016.
The share buy-back program is expected to be realized in the period from February 26, 2025, to August 15, 2025. The total transaction value of the share buy-backs in the period will not exceed DKK 250m.
The following transactions on Nasdaq Copenhagen A/S have been made under the program:
| Number of Shares | Average purchase price DKK | Transaction value, DKK | |
| Accumulated, last announcement | 57,947 | 548.88 | 31,806,110 |
| March 24, 2025 | 5,000 | 540.98 | 2,704,886 |
| March 25, 2025 | 7,000 | 535.16 | 3,746,133 |
| March 26, 2025 | 8,000 | 531.36 | 4,250,848 |
| March 27, 2025 | 3,000 | 550.99 | 1,652,984 |
| March 28, 2025 | 3,000 | 551.60 | 1,654,795 |
| Total accumulated under the program | 83,947 | 545.77 | 45,815,756 |
With the transactions stated above Royal Unibrew owns a total of 217,342 shares, corresponding to 0.4% of the share capital. The total amount of shares in the company is 50,200,000, including treasury shares.
For further information please contact:
Flemming Ole Nielsen (Head of Investor Relations)
E-mail: Flemming.Nielsen@royalunibrew.com
Telephone: +45 25 41 68 04
Encl.
Attachments
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
ProvaDent2.4.2025 03:18:11 CEST | Press release
ProvaDent Reviews (DENTIST INVESTIGATED): Can This Oral Probiotic Really Strengthen Teeth and Reverse Years of Damage?
Tenaris SA2.4.2025 00:05:53 CEST | Press release
Tenaris Files 2024 Annual Report / Annual Report on Form 20-F, and Convenes the Annual General Meeting of Shareholders and an Extraordinary General Meeting of Shareholders
INVENTIVA1.4.2025 23:00:00 CEST | Press release
Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis
Respilean1.4.2025 22:30:10 CEST | Press release
Respilean Review (BREAKING NEWS): Why Thousands Are Calling It the Natural Lung Breakthrough of 2025
nCino, Inc.1.4.2025 22:06:00 CEST | Press release
nCino Reports Fourth Quarter and Fiscal Year 2025 Financial Results
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom